Here's Why Veracyte ( VCYT ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte ( VCYT ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care
Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test
Veracyte ( VCYT ) Q2 Revenue Jumps 14%
Veracyte ( NASDAQ:VCYT ) , a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and profitability, driven by strong expansion in its core prostate cancer genomic testing platform.
Veracyte ( VCYT ) Tops Q2 Earnings and Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of +41.94% and +7.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood's $15M Crypto Bet: Sells Bitcoin King Block, Doubles Down On Ethereum Giant Bitmine Immersion - Grayscale Ethereum Mini Trust ( ETH ) Common units of fractional undivided beneficial interest ( ARCA:ETH )
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, focusing on Bitmine Immersion Technologies Inc. BMNR and Block Inc. XYZ. These trades reflect Ark's strategic positioning in the market amidst evolving financial landscapes.
Cathie Wood Goes On A $20M Bitmine Immersion Bargain Hunt As Ark Trims Robinhood And Palantir Stakes - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made significant trades, including a notable purchase of Bitmine Immersion Technologies Inc. ( BMNR ) shares. The investment firm also increased its holdings in Alphabet Inc. GOOG and NVIDIA Corp NVDA, while reducing its stake in Robinhood Markets Inc.
Veracyte ( VCYT ) Soars 7.0%: Is Further Upside Left in the Stock?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest made notable trades on Wednesday, focusing on Shopify Inc. SHOP and Robinhood Markets Inc. HOOD.
Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )
Cathie Wood-led Ark Invest made significant trades on Tuesday, spotlighting its strategic acquisitions of Shopify Inc. SHOP and Airbnb Inc. ABNB. These trades reflect Ark's continued interest in high-growth technology and e-commerce sectors.
Cathie Wood Dumps $1.8 Million In Coinbase Stock As Bitcoin Nears $110K All-Time High - ARK Fintech Innovation ETF ( BATS:ARKF )
On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc. COIN across its ETFs. This decision comes as Coinbase has been riding a wave of optimism in the cryptocurrency market, fueled by Bitcoin's BTC/USD ascent and Coinbase's recent inclusion in the S&P ...
Veracyte ( VCYT ) Down 13.6% Since Last Earnings Report: Can It Rebound?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cathie Wood Drops $373 Million On Circle's 168% Rally, Dumps Coinbase And Crypto Holdings - Is Ark Ditching Bitcoin for Stablecoins? - ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests ( BATS:ARKB )
Cathie Wood's Ark Invest made a blockbuster purchase of Circle Internet Group CRCL shares on Thursday, marking a significant move in the evolving digital assets landscape. The bold acquisition came as Ark simultaneously reshuffled its cryptocurrency stock portfolio, reducing exposure to other ...
Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy - ARK Innovation ETF ( BATS:ARKK ) , Palantir Technologies ( NASDAQ:PLTR )
On Wednesday, Cathie Wood's Ark Invest made a significant move by selling a substantial number of shares in Palantir Technologies Inc. PLTR. This decision comes amidst a brewing controversy surrounding the company's alleged involvement in a surveillance program.
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Cathie Wood's $21.5 Million Shopify Grab Defies Post-Earnings Dip, Ark Continues Dumping Palantir, Also Chops Jack Dorsey's Block - ARK Fintech Innovation ETF ( BATS:ARKF )
On Thursday, Cathie Wood-led Ark Invest made significant moves in the stock market, focusing on Shopify Inc. SHOP, Palantir Technologies Inc. PLTR, and Block Inc. XYZ.
What Makes Veracyte ( VCYT ) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Veracyte ( VCYT ) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 55% and 3.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics ( EKSO ) Reports Q1 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -9.09% and 28.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
On Friday, Cathie Wood-led Ark Invest made several significant trades. The most prominent among these involved the buying and selling of shares in Intellia Therapeutics Inc. NTLA, Meta Platforms Inc. META, Veracyte Inc. VCYT, Symbotic Inc. SYM, Baidu Inc. BIDU, and UiPath Inc. PATH.
Should You Continue to Hold Veracyte Stock in Your Portfolio?
Strength in the Afirma and Decipher franchises continues to bode well for VCYT stock.
International Growth Drives GMED Stock Amid Fierce Competition
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Bruker Stock May Benefit Following Its Investment in Ridom GmbH
BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.
Bruker Debuts Fourier 80 Multinuclear Benchtop FT-NMR: Stock to Gain?
BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.
Veracyte ( VCYT ) Just Overtook the 20-Day Moving Average
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Strength Seen in Veracyte ( VCYT ) : Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Is This the Right Time to Hold ALGN Stock in Your Portfolio?
Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
National Vision Stock Rises 28.2% YTD: Will the Rally Continue?
EYE's strength in its largest brand and actions to achieve a healthier store fleet position the stock favorably.
Veracyte ( VCYT ) Up 0.7% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Veracyte ( VCYT ) Could Rally 35.05%: Here's is How to Trade
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is This the Right Time to Hold Integra Stock in Your Portfolio?
IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Should You Retain IDEXX Stock in Your Portfolio for Now?
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Myriad Genetics ( NASDAQ:MYGN )
Piper Sandler upgrades Myriad Genetics to Overweight, raising the price target to $12.50 from $11.50. Myriad Genetics plans to launch a new AI-integrated prostate test later this year or early next year. Find out which stock just plummeted to the bottom of the new Benzinga Rankings.
Should You Continue to Retain STERIS Stock in Your Portfolio Now?
Investors continue to keep an eye on STE due to its promising Healthcare arm and AST segment's prospects.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Veracyte ( NASDAQ:VCYT )
Veracyte's Q4 testing revenue rose 24% YoY to $112.2 million, with test volume up 25% to 39,107. The French unit generates $4 million per quarter but incurs $7 million in fixed costs, leading to a $5 million loss.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte ( VCYT ) Q4 Earnings and Revenues Beat Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 24.14% and 1.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
